Middle East And Africa Multiple Sclerosis Treatment Market
시장 규모 (USD 10억)
연평균 성장률 :
% 
 예측 기간 |
2022 –2029 |
 시장 규모(기준 연도) |
USD 235.54 Million |
 시장 규모(예측 연도) |
USD 348.00 Million |
 연평균 성장률 |
% |
| 주요 시장 플레이어 |
>중동 및 아프리카 다발성 경화증 치료 시장, 유형별(임상적으로 고립된 증후군(CIS), 재발 완화형 MS(RRMS), 1차 진행성 MS(PPMS), 2차 진행성 MS(SPMS)), 치료(약물, 줄기세포 치료, 물리 치료 , 혈장 교환, 기타), 약물 종류(면역 조절제, 면역 억제제, 인터페론, 기타), 진단(자기 공명 영상(MRI), 단순 전기 자극 검사, 요추 천자, 기타), 투여 경로(경구, 비경구, 기타), 최종 사용자(병원, 전문 병원, 홈 케어, 기타), 유통 채널(병원 약국, 소매 약국, 온라인 약국, 기타) - 2029년까지의 산업 동향 및 예측
시장 분석 및 규모
National Multiple Sclerosis Society에 따르면, 다발성 경화증은 미국에서 약 100만 명, 전 세계적으로 230만 명에게 영향을 미칩니다. 매년 다발성 경화증 진단을 받는 사람의 수가 증가함에 따라, 더 효과적이고 부작용이 적은 새로운 약물의 개발이 필요해지고 있습니다. 선진국과 개발도상국의 정부와 비정부 기구는 다발성 경화증에 대한 인식을 높이고 약물 연구 및 개발을 위한 상당한 기금을 제공하기 위한 노력을 강화하고 있습니다.
Data Bridge Market Research는 다발성 경화증 치료 시장이 2021년에 2억 3,554만 달러 규모였으며 2029년까지 3억 4,800만 달러에 도달할 것으로 예상하고 2022년부터 2029년까지의 예측 기간 동안 5.00%의 CAGR을 기록할 것으로 분석했습니다. Data Bridge Market Research 팀이 큐레이팅한 시장 보고서에는 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크가 포함되어 있습니다.
보고 범위 및 시장 세분화
|
보고서 메트릭 |
세부 |
|
예측 기간 |
2022년부터 2029년까지 |
|
기준 연도 |
2021 |
|
역사적 연도 |
2020 (2019-2014까지 사용자 정의 가능) |
|
양적 단위 |
매출은 백만 달러, 볼륨은 단위, 가격은 달러로 표시됨 |
|
다루는 세그먼트 |
유형별(임상적으로 고립된 증후군(CIS), 재발 완화형 MS(RRMS), 1차 진행성 MS(PPMS), 2차 진행성 MS(SPMS)), 치료(약물, 줄기세포 치료, 물리 치료, 혈장 교환, 기타), 약물 종류(면역 조절제, 면역 억제제, 인터페론, 기타), 진단(자기 공명 영상(MRI), 단순 전기 자극 검사, 요추 천자, 기타), 투여 경로(경구, 비경구, 기타), 최종 사용자(병원, 전문 병원, 홈 케어, 기타), 유통 채널(병원 약국, 소매 약국, 온라인 약국, 기타) |
|
적용 국가 |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
|
Market Players Covered |
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd.(Ireland), Sanofi (France), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Bayer AG (Germany), Hikma Pharmaceuticals PLC (UK), Merck KGaA (Germany) |
|
Market Opportunities |
|
Market Definition
Multiple sclerosis (MS) is a chronic inflammatory immune-mediated disease that affects spinal cord and brain nerve cells, causing demyelination, axonal transection, and neurodegeneration. Injectable, oral, and infused medications, muscle relaxants, antidepressants, and physical therapy are some of the most widely utilized therapies. Interferon-beta and glatiramer acetate are injectable therapies that are given under the skin or into the muscle; oral medications include teriflunomide, dimethyl fumarate, and cladribine; and intravenous infusion treatments include ocrelizumab, alemtuzumab and natalizumab.
Middle East and Africa Multiple Sclerosis Treatment Market Dynamics
Drivers
- Increasing prevalence of multiple sclerosis
The rising prevalence of multiple sclerosis is a primary driver of the multiple sclerosis treatment market's growth. Relapsing-remitting multiple sclerosis (RRMS), primary-progressive MS (PPMS), secondary-progressive MS (SPMS) and progressive-relapsing MS (PRMS) are the types of multiple sclerosis and their high prevalence rate will influence the market dynamics during the forecast period.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of multiple sclerosis treatment market is the rising healthcare expenditure which helps in improving its infrastructure.
Furthermore, rising initiatives by public and private organizations to spread awareness will expand the multiple sclerosis treatment market. Additionally, high disposable income and increase in the development of innovative monoclonal antibodies, immunosuppressants, immunomodulators, and interferons will expand the multiple sclerosis treatment market. Along with this, rising geriatric population and continuously changing lifestyle will enhance the market's growth rate.
Opportunities
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the multiple sclerosis treatment market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate.
Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will further provide beneficial opportunities for the growth of the multiple sclerosis treatment market during the forecast period.
Restraints/Challenges
On the other hand, the high cost associated with the treatment of multiple sclerosis will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the multiple sclerosis treatment market. Additionally, a decline in clinical visits due to COVID0-19 outbreak and lack of awareness among people will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This Middle East and Africa multiple sclerosis treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Middle East and Africa multiple sclerosis treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Multiple sclerosis treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Middle East and Africa Multiple Sclerosis Treatment Market
2019년 12월에 출현한 이래 COVID-19 바이러스는 지구상 거의 모든 국가로 퍼져 세계보건기구(WHO)가 이를 공중보건 비상사태로 선언하게 되었습니다. 재정 위기와 COVID-19 관련 치료를 우선시하는 동안 전문 의료 서비스 제공이 지연되면서 전 세계의 의료 시스템은 코로나바이러스 팬데믹의 여파로 심각하게 중단되었습니다. 환자들은 의사를 만나는 데 어려움, 감염 전파에 대한 두려움, 팬데믹 제한으로 인해 치료와 필수 시술을 계속할 수 없음 등 다양한 이유로 검사를 받을 수 없었습니다. 이러한 고려 사항은 최근 몇 달 동안 중동 및 아프리카 다발성 경화증 시장에 부정적인 영향을 미칠 수 있습니다.
최근 개발
- 2020년 8월, 노바티스는 미국 식품의약국(FDA) 승인을 받아 케심프타(오파투무맙)를 출시한다고 발표했습니다. 재발성 다발성 경화증을 앓고 있는 사람들을 위한 최초이자 유일한 자가 투여형 표적 B세포 요법입니다. 케심프타는 강력한 효능과 허용 가능한 안전 프로필을 결합하며, 집에서 자가 투여할 수 있어, 다발성 경화증(RMS)의 대체 형태 치료에 있어 중요한 격차를 메웁니다.
중동 및 아프리카 다발성 경화증 치료 시장 범위
중동 및 아프리카 다발성 경화증 치료 시장은 유형, 약물 종류, 치료, 진단, 투여 경로, 최종 사용자 및 유통 채널을 기준으로 세분화됩니다. 이러한 세그먼트 간의 성장은 산업의 빈약한 성장 세그먼트를 분석하고 사용자에게 귀중한 시장 개요와 시장 통찰력을 제공하여 핵심 시장 응용 프로그램을 식별하기 위한 전략적 결정을 내리는 데 도움이 됩니다.
유형
- 임상적으로 고립된 증후군(CIS)
- 재발-완화형 MS(RRMS)
- 1차 진행성 MS(PPMS)
- 2차 진행성 MS(SPMS)
치료
- 약물
- 주사 치료
- 인터페론-베타
- 글라티라머 아세테이트
- 경구 약물
- 디메틸푸마르산염
- 테리플루노마이드
- 클라드리빈
- 정맥 주입 치료
- 오크렐리주맙
- 나탈리주맙
- 알렘투주맙
- 줄기세포 치료
- 물리 치료
- 플라스마 교환
- 기타
약물 종류
- 면역 조절제
- 면역억제제
- 인터페론
- 기타
진단
- 자기공명영상(MRI)
- 간단한 전기 자극 테스트
- 요추 천자
- 기타
투여 경로
- 경구
- 비경구적
- 기타
최종 사용자
- 병원
- 전문 클리닉
- 홈케어
- 기타
유통 채널
- 병원 약국
- 소매 약국
- 온라인 약국
- 기타
중동 및 아프리카 다발성 경화증 치료 시장 지역 분석/통찰력
중동 및 아프리카 다발성경화증 치료 시장을 분석하고, 위에 언급된 대로 국가, 유형, 치료, 약물 종류, 진단, 투여 경로, 최종 사용자 및 유통 채널별로 시장 규모에 대한 통찰력과 추세를 제공합니다.
중동 및 아프리카 다발성경화증 치료 시장 보고서에서 다루는 국가는 사우디아라비아, UAE, 남아프리카공화국, 이집트, 이스라엘, 중동 및 아프리카(MEA)의 일부인 기타 중동 및 아프리카(MEA)입니다.
남아프리카공화국은 다발성 경화증에 대한 인식이 높아지고 이 지역에서 의료비 지출이 증가함에 따라 2022~2029년 중동 및 아프리카 지역에서 성장할 것으로 예상됩니다.
보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 다운스트림 및 업스트림 가치 사슬 분석, 기술 트렌드 및 포터의 5가지 힘 분석, 사례 연구와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 몇 가지 포인터입니다. 또한 중동 및 아프리카 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 국내 관세 및 무역 경로의 영향은 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.
경쟁 환경 및 중동 및 아프리카 다발성 경화증 치료 시장 점유율 분석
중동 및 아프리카 다발성 경화증 치료 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 중동 및 아프리카의 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우세입니다. 제공된 위의 데이터 포인트는 중동 및 아프리카 다발성 경화증 치료 시장과 관련된 회사의 초점에만 관련이 있습니다.
중동 및 아프리카 다발성 경화증 치료 시장에서 활동하는 주요 기업은 다음과 같습니다.
- F. 호프만-라 로슈 유한회사(스위스)
- 마일런 NV(미국)
- Teva Pharmaceutical Industries Ltd.(아일랜드)
- 사노피(프랑스)
- 파이저 주식회사(미국)
- GlaxoSmithKline plc (영국)
- 노바티스 AG(스위스)
- Bayer AG(독일)
- 엘리 릴리 앤드 컴퍼니(미국)
- 머크 KGaA(독일)
- 히크마 제약(영국)
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 DISEASE TYPE LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 SECONDARY SOURCES
2.11 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: REGULATIONS
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 INCREASING PREVALENCE OF MULTIPLE SCLEROSIS
5.1.2 EXTENSIVE RESEARCH AND DEVELOPMENT ACTIVITY IN MULTIPLE SCLEROSIS TREATMENT
5.1.3 RISING GOVERNMENT INITIATIVES
5.1.4 INCREASING NEED FOR BETTER MULTIPLE SCLEROSIS TREATMENT OPTIONS
5.2 RESTRAINTS
5.2.1 PATENT EXPIRY OF DRUGS
5.2.2 HIGH COST OF TREATMENT
5.3 OPPORTUNITIES
5.3.1 INCREASING AWARENESS FOR MULTIPLE SCLEROSIS TREATMENT
5.3.2 INTRODUCTION OF DISEASE-MODIFYING DRUGS
5.3.3 PRESENCE OF STRONG PIPELINE DRUGS
5.4 CHALLENGES
5.4.1 INCREASING SIDE EFFECT OF MULTIPLE SCLEROSIS MEDICATION
5.4.2 LIMITATIONS IN MULTIPLE SCLEROSIS THERAPY
6 COVID-19 IMPACT ON MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET IN HEALTHCARE INDUSTRY
6.1 OVERVIEW
6.2 PRICE IMPACT
6.3 IMPACT ON DEMAND
6.4 IMPACT ON SUPPLY CHAIN
6.5 STRATEGIC DECISIONS FOR MANUFACTURERS
6.6 CONCLUSION
7 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE
7.1 OVERVIEW
7.1 RELAPSING–REMITTING MULTIPLE SCLEROSIS (RRMS)
7.2 SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS (SPMS)
7.3 PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS (PPMS)
7.4 SEVERE RELAPSING–REMITTING MULTIPLE SCLEROSIS (RES)
8 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT
8.1 OVERVIEW
8.2 PREVENTIVE THERAPIES
8.2.1 ORAL MEDICATION
8.2.1.1 TECFIDERA
8.2.1.2 GILENYA
8.2.1.3 AUBAGIO
8.2.1.4 MAVENCLAD
8.2.1.5 MAYZENT
8.2.1.6 VUMERITY
8.2.1.7 OTHERS
8.2.2 INJECTABLE MEDICATION
8.2.2.1 INTERFERON BETA-1A
8.2.2.1.1 AVONEX
8.2.2.1.2 REBIF
8.2.2.1.3 OTHERS
8.2.2.2 GLATIRAMER ACETATE
8.2.2.2.1 COPAXONE
8.2.2.2.2 GLATOPA
8.2.2.2.3 OTHERS
8.2.2.3 INTERFERON BETA-1B
8.2.2.3.1 BETASERON
8.2.2.3.2 EXTAVIA
8.2.2.4 PLEGRIDY/PEGINTERFERON BETA-1A
8.2.2.5 CHEMOTHERAPY DRUG
8.2.2.6 MONOCLONAL ANTIBODIES
8.2.3 INFUSED MEDICATION
8.2.3.1 TYSABRI
8.2.3.2 OCREVUS
8.2.3.3 LEMTRADA
8.2.3.4 MITOXANTRONE
8.2.3.5 NOVANTRONE
8.2.3.6 OTHERS
8.2.4 HAEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
8.3 ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS
8.3.1 CORTICOSTEROIDS
8.3.1.1 ORAL PREDNISONE
8.3.1.2 METHYLPREDNISOLONE
8.3.1.3 DEXAMETHASONE
8.3.1.4 PREDNISOLONE
8.3.1.5 BETAMETHASONE
8.3.1.6 OTHERS
8.3.2 IMMUNOSUPPRESSANTS
8.3.2.1 AZATHIOPRINE
8.3.2.2 CYCLOPHOSPHAMIDE
8.3.2.3 METHOTREXATE
8.3.2.4 MITOXANTRONE
8.3.2.5 OTHERS
8.3.3 ADRENOCORTICOTROPIC HORMONE
8.3.4 PLASMAPHERESIS
8.3.5 INTRAVENOUS IMMUNOGLOBULIN
8.3.6 OTHERS
8.4 SYMPTOMATIC THERAPIES
8.4.1.1 MUSCLE RELAXANTS
8.4.1.1.1 LIORESAL
8.4.1.1.2 ZANAFLEX
8.4.1.1.3 OTHERS
8.4.1.2 FATIGUE MEDICATIONS
8.4.1.2.1 GOCOVRI
8.4.1.2.2 OSMOLEX
8.4.1.2.3 PROVIGIL
8.4.1.2.4 RITALIN
8.4.1.2.5 OTHERS
8.4.1.3 PHYSIOTHERAPY
8.4.1.4 LAXATIVES
9 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE
9.1 OVERVIEW
9.2 BRANDED
9.2.1 TECFIDERA
9.2.2 GILENYA
9.2.3 AUBAGIO
9.2.4 AVONEX
9.2.5 TYSABRI
9.2.6 REBIF
9.2.7 COPAXONE
9.2.8 8 BETASERON
9.2.9 AMPYRA/FAMPYRA
9.2.10 OTHERS
9.3 GENERIC
10 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
10.1 OVERVIEW
10.2 ORAL
10.3 PARENTERAL
10.3.1 INTRAVENOUS
10.3.2 SUBCUTANEOUS
10.3.3 OTHERS
11 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS
11.3 HOMECARE
11.4 SPECIALTY CENTERS
11.5 OTHERS
12 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 RETAIL SALES
12.2.1 RETAIL PHARMACY
12.2.2 HOSPITAL PHARMACY
12.3 DIRECT TENDER
13 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY GEOGRAPHY
13.1 MIDDLE EAST & AFRICA
13.1.1 SAUDI ARABIA
13.1.2 SOUTH AFRICA
13.1.3 UAE
13.1.4 ISRAEL
13.1.5 KUWAIT
13.1.6 EGYPT
13.1.7 REST OF MIDDLE EAST & AFRICA
14 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
15 SWOT
16 COMPANY PROFILES
16.1 BIOGEN
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENT
16.2 NOVARTIS AG
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENTS
16.3 GENZYME CORPORATION (A SUBSIDIARY OF SANOFI)
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENTS
16.4 MERCK KGAA
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 COMPANY SHARE ANALYSIS
16.4.4 PRODUCT PORTFOLIO
16.4.5 RECENT DEVELOPMENTS
16.5 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICALS INDUSTRIES LTD.)
16.5.1 COMPANY SNAPSHOT
16.5.2 REVENUE ANALYSIS
16.5.3 COMPANY SHARE ANALYSIS
16.5.4 PRODUCT PORTFOLIO
16.5.5 RECENT DEVELOPMENTS
16.6 F. HOFFMANN-LA ROCHE LTD
16.6.1 COMPANY SNAPSHOT
16.6.2 REVENUE ANALYSIS
16.6.3 PRODUCT PORTFOLIO
16.6.4 RECENT DEVELOPMENTS
16.7 ACORDA THERAPEUTICS, INC.
16.7.1 COMPANY SNAPSHOT
16.7.2 REVENUE ANALYSIS
16.7.3 PRODUCT PORTFOLIO
16.7.4 1.7.4 RECENT DEVELOPMENT
16.8 ADAMAS PHARMACEUTICALS, INC.
16.8.1 COMPANY SNAPSHOT
16.8.2 REVENUE ANALYSIS
16.8.3 PRODUCT PORTFOLIO
16.8.4 RECENT DEVELOPMENT
16.9 AMNEAL PHARMACEUTICALS LLC
16.9.1 COMPANY SNAPSHOT
16.9.2 REVENUE ANALYSIS
16.9.3 PRODUCT PORTFOLIO
16.9.4 RECENT DEVELOPMENT
16.1 BAYER AG
16.10.1 COMPANY SNAPSHOT
16.10.2 1.10.2REVENUE ANALYSIS
16.10.3 PRODUCT PORTFOLIO
16.10.4 RECENT DEVELOPMENT
16.11 CELGENE CORPORATION (A SUBSIDIARY OF BRISTOL-MYERS SQUIBB COMPANY)
16.11.1 COMPANY SNAPSHOT
16.11.2 REVENUE ANALYSIS
16.11.3 PRODUCT PORTFOLIO
16.11.4 RECENT DEVELOPMENTS
16.12 HIKMA PHARMACEUTICALS PLC
16.12.1 COMPANY SNAPSHOT
16.12.2 REVENUE ANALYSIS
16.12.3 PRODUCT PORTFOLIO
16.12.4 RECENT DEVELOPMENTS
16.13 LANNETT
16.13.1 COMPANY SNAPSHOT
16.13.2 REVENUE ANALYSIS
16.13.3 PRODUCT PORTFOLIO
16.13.4 RECENT DEVELOPMENT
16.14 MALLINCKRODT
16.14.1 COMPANY SNAPSHOT
16.14.2 REVENUE ANALYSIS
16.14.3 PRODUCT PORTFOLIO
16.14.4 RECENT DEVELOPMENTS
16.15 MYLAN N.V.
16.15.1 COMPANY SNAPSHOT
16.15.2 REVENUE ANALYSIS
16.15.3 PRODUCT PORTFOLIO
16.15.4 RECENT DEVELOPMENTS
16.16 PAR PHARMACEUTICAL (A SUBSIDIARY OF ENDO INTERNATIONAL PLC)
16.16.1 COMPANY SNAPSHOT
16.16.2 REVENUE ANALYSIS
16.16.3 PRODUCT PORTFOLIO
16.16.4 RECENT DEVELOPMENTS
16.17 PFIZER INC.
16.17.1 COMPANY SNAPSHOT
16.17.2 REVENUE ANALYSIS
16.17.3 PRODUCT PORTFOLIO
16.17.4 RECENT DEVELOPMENTS
16.18 ZYDUS PHARMACEUTICALS, INC. (A SUBSIDIARY OF ZYDUS CADILA)
16.18.1 COMPANY SNAPSHOT
16.18.2 REVENUE ANALYSIS
16.18.3 PRODUCT PORTFOLIO
16.18.4 RECENT DEVELOPMENT
17 QUESTIONNAIRE
18 RELATED REPORTS
표 목록
LIST OF TABLES
TABLE 1 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, PIPELINE ANALYSIS
TABLE 2 MULTIPLE SCLEROSIS DRUGS IN PIPELINE
TABLE 3 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
TABLE 1 MIDDLE EAST AND AFRICA RELAPSING–REMITTING MULTIPLE SCLEROSIS (RRMS) IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 2 MIDDLE EAST AND AFRICA SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS (SPMS) IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 3 MIDDLE EAST AND AFRICA PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS (PPMS) IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 4 MIDDLE EAST AND AFRICA SEVERE RELAPSING–REMITTING MULTIPLE SCLEROSIS (RES) IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 5 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 6 MIDDLE EAST AND AFRICA PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 7 MIDDLE EAST AND AFRICA PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 8 MIDDLE EAST AND AFRICA ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 9 MIDDLE EAST AND AFRICA INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 10 MIDDLE EAST AND AFRICA INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 11 MIDDLE EAST AND AFRICA GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 12 MIDDLE EAST AND AFRICA INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 13 MIDDLE EAST AND AFRICA INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 14 MIDDLE EAST AND AFRICA ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 15 MIDDLE EAST AND AFRICA ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 16 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 17 MIDDLE EAST AND AFRICA IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 18 MIDDLE EAST AND AFRICA SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 19 MIDDLE EAST AND AFRICA SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 20 MIDDLE EAST AND AFRICA MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 21 MIDDLE EAST AND AFRICA FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 22 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 23 MIDDLE EAST AND AFRICA BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 24 MIDDLE EAST AND AFRICA BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)
TABLE 25 MIDDLE EAST AND AFRICA GENERIC IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 26 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 27 MIDDLE EAST AND AFRICA ORAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 28 MIDDLE EAST AND AFRICA PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 29 MIDDLE EAST AND AFRICA PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY RUOTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 30 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 31 MIDDLE EAST AND AFRICA HOSPITAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 32 MIDDLE EAST AND AFRICA HOMECARE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 33 MIDDLE EAST AND AFRICA SPECIALTY CENTERS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 34 MIDDLE EAST AND AFRICA OTHERS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 35 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 36 MIDDLE EAST AND AFRICA RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 37 MIDDLE EAST AND AFRICA RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 38 MIDDLE EAST AND AFRICA DIRECT TENDER IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 39 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 40 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
TABLE 41 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 42 MIDDLE EAST & AFRICA PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 43 MIDDLE EAST & AFRICA ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 44 MIDDLE EAST & AFRICA INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 45 MIDDLE EAST & AFRICA INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 46 MIDDLE EAST & AFRICA GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 47 MIDDLE EAST & AFRICA INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 48 MIDDLE EAST & AFRICA INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 49 MIDDLE EAST & AFRICA ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 50 MIDDLE EAST & AFRICA CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 51 MIDDLE EAST & AFRICA IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 52 MIDDLE EAST & AFRICA SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 53 MIDDLE EAST & AFRICA MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 54 MIDDLE EAST & AFRICA FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 55 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 56 MIDDLE EAST & AFRICA BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)
TABLE 57 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 58 MIDDLE EAST & AFRICA PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 59 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 60 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 61 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 62 SAUDI ARABIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
TABLE 63 SAUDI ARABIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 64 SAUDI ARABIA PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 65 SAUDI ARABIA ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 66 SAUDI ARABIA INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 67 SAUDI ARABIA INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 68 SAUDI ARABIA GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 69 SAUDI ARABIA INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 70 SAUDI ARABIA INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 71 SAUDI ARABIA ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 72 SAUDI ARABIA CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 73 SAUDI ARABIA IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 74 SAUDI ARABIA SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 75 SAUDI ARABIA MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 76 SAUDI ARABIA FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 77 SAUDI ARABIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 78 SAUDI ARABIA BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)
TABLE 79 SAUDI ARABIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 80 SAUDI ARABIA PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 81 SAUDI ARABIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 82 SAUDI ARABIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 83 SAUDI ARABIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 84 SOUTH AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
TABLE 85 SOUTH AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 86 SOUTH AFRICA PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 87 SOUTH AFRICA ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 88 SOUTH AFRICA INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 89 SOUTH AFRICA GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 90 SOUTH AFRICA INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 91 SOUTH AFRICA INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 92 SOUTH AFRICA ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 93 SOUTH AFRICA CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 94 SOUTH AFRICA IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 95 SOUTH AFRICA SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 96 SOUTH AFRICA MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 97 SOUTH AFRICA FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 98 SOUTH AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 99 SOUTH AFRICA BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)
TABLE 100 SOUTH AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 101 SOUTH AFRICA PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 102 SOUTH AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 103 SOUTH AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 104 SOUTH AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 105 UAE MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
TABLE 106 UAE MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 107 UAE PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 108 UAE ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 109 UAE INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 110 UAE INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 111 UAE GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 112 UAE INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 113 UAE INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 114 UAE ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 115 UAE CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 116 UAE IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 117 UAE SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 118 UAE MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 119 UAE FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 120 UAE MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 121 UAE BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)
TABLE 122 UAE MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 123 UAE PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 124 UAE MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 125 UAE MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 126 UAE MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 127 ISRAEL MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
TABLE 128 ISRAEL MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 129 ISRAEL PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 130 ISRAEL ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 131 ISRAEL INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 132 ISRAEL INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 133 ISRAEL GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 134 ISRAEL INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 135 ISRAEL INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 136 ISRAEL ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 137 ISRAEL CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 138 ISRAEL IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 139 ISRAEL SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 140 ISRAEL MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 141 ISRAEL FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 142 ISRAEL MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 143 ISRAEL BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)
TABLE 144 ISRAEL MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 145 ISRAEL PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 146 ISRAEL MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 147 ISRAEL MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 148 ISRAEL MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 149 KUWAIT MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
TABLE 150 KUWAIT MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 151 KUWAIT PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 152 KUWAIT ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 153 KUWAIT INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 154 KUWAIT INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 155 KUWAIT GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 156 KUWAIT INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 157 KUWAIT INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 158 KUWAIT ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 159 KUWAIT CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 160 KUWAIT IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 161 KUWAIT SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 162 KUWAIT MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 163 KUWAIT FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 164 KUWAIT MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 165 KUWAIT BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)
TABLE 166 KUWAIT MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 167 KUWAIT PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 168 KUWAIT MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 169 KUWAIT MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 170 KUWAIT MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 171 EGYPT MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
TABLE 172 EGYPT MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 173 EGYPT PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 174 EGYPT ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 175 EGYPT INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 176 EGYPT INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 177 EGYPT GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 178 EGYPT INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 179 EGYPT INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 180 EGYPT ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 181 EGYPT CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 182 EGYPT IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 183 EGYPT SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 184 EGYPT MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 185 EGYPT FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 186 EGYPT MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 187 EGYPT BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)
TABLE 188 EGYPT MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 189 EGYPT PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 190 EGYPT MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 191 EGYPT MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 192 EGYPT MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 193 REST OF MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
그림 목록
LIST OF FIGURES
FIGURE 1 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 8 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: SEGMENTATION
FIGURE 10 INCREASING PREVALENCE OF MULTIPLE SCLEROSIS AND RISING GOVERNMENT INITIATIVES ARE EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET IN THE FORECAST PERIOD OF 2020 TO 2027
FIGURE 11 RELAPSING–REMITTING MULTIPLE SCLEROSIS (RRMS) SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET IN 2020 & 2027
FIGURE 12 PIPELINE ANALYSIS
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET
FIGURE 14 MULTIPLE SCLEROSIS PREVALENCE
FIGURE 15 MULTIPLE SCLEROSIS PREVALENCE BY GENDER
FIGURE 16 PIPELINE BY DEVELOPMENT PHASE, 2019 VERSUS 2018
FIGURE 17 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY DISEASE TYPE, 2019
FIGURE 18 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY DISEASE TYPE, 2019-2027 (USD MILLION)
FIGURE 19 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY DISEASE TYPE, CAGR (2020-2027)
FIGURE 20 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY DISEASE TYPE, LIFELINE CURVE
FIGURE 21 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY TREATMENT, 2019
FIGURE 22 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY TREATMENT, 2019-2027 (USD MILLION)
FIGURE 23 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY TREATMENT, CAGR (2020-2027)
FIGURE 24 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 25 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY DRUG TYPE, 2019
FIGURE 26 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2019-2027 (USD MILLION)
FIGURE 27 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY DRUG TYPE, CAGR (2020-2027)
FIGURE 28 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 29 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2019
FIGURE 30 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)
FIGURE 31 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2027)
FIGURE 32 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 33 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY END USER, 2019
FIGURE 34 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2019-2027 (USD MILLION)
FIGURE 35 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY END USER, CAGR (2020-2027)
FIGURE 36 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 37 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2019
FIGURE 38 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
FIGURE 39 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2027)
FIGURE 40 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 41 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: SNAPSHOT (2019)
FIGURE 42 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY COUNTRY (2019)
FIGURE 43 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY COUNTRY (2020 & 2027)
FIGURE 44 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY COUNTRY (2019 & 2027)
FIGURE 45 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY TYPE (2020-2027)
FIGURE 46 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: COMPANY SHARE 2019 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.
